The role of microRNA in modulating myocardial ischemia-reperfusion injury

Yumei Ye, Jose R. Perez-Polo, Jinqiao Qian, Yochai Birnbaum

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

MicroRNAs (miRNAs) are small (~22 nt) noncoding single-stranded RNA molecules that downregulate gene expression. Studies have shown that miRNAs control diverse aspects of heart disease, including hypertrophy, remodeling, heart failure, and arrhythmia. Recently, several studies have suggested that miRNAs contribute to ischemia-reperfusion injury by altering key signaling elements, thus making them potential therapeutic targets. By altering the expression of various key elements in cell survival and apoptosis [such as phosphoinositide 3-kinase (PI3K), phosphatase and tensin homolog deleted on chromosome 10 (PTEN), Bcl-2, Mcl-1, heat shock protein (HSP)60, HSP70, HSP20, programmed cell death 4 (Pdcd4), LRRFIP1, Fas ligand (FasL), Sirt-1, etc.], miRNAs alter the response to ischemia-reperfusion injury. Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a, miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction. Thus miRNAs could be potential therapeutic targets for the treatment of heart disease. Inhibiting miRNAs by antisense strategies or pharmacological approaches is likely to emerge as an alternative and safe method for conferring short- and intermediate-term protection against ischemia-reperfusion injury.

Original languageEnglish (US)
Pages (from-to)534-542
Number of pages9
JournalPhysiological Genomics
Volume43
Issue number10
DOIs
StatePublished - May 2011

Fingerprint

Myocardial Reperfusion Injury
Reperfusion Injury
MicroRNAs
Myocardial Ischemia
Heart Diseases
HSP72 Heat-Shock Proteins
Chaperonin 60
Chromosomes, Human, Pair 10
Fas Ligand Protein
1-Phosphatidylinositol 4-Kinase
Phosphoric Monoester Hydrolases
Hypertrophy
Cardiac Arrhythmias
Cell Survival
Cell Death
Down-Regulation
Heart Failure
Myocardial Infarction
Pharmacology
RNA

Keywords

  • Infarct size
  • Myocardial infarction

ASJC Scopus subject areas

  • Physiology
  • Genetics

Cite this

The role of microRNA in modulating myocardial ischemia-reperfusion injury. / Ye, Yumei; Perez-Polo, Jose R.; Qian, Jinqiao; Birnbaum, Yochai.

In: Physiological Genomics, Vol. 43, No. 10, 05.2011, p. 534-542.

Research output: Contribution to journalArticle

Ye, Yumei ; Perez-Polo, Jose R. ; Qian, Jinqiao ; Birnbaum, Yochai. / The role of microRNA in modulating myocardial ischemia-reperfusion injury. In: Physiological Genomics. 2011 ; Vol. 43, No. 10. pp. 534-542.
@article{a62458c93cc84540bc6e044bcd8a1cb0,
title = "The role of microRNA in modulating myocardial ischemia-reperfusion injury",
abstract = "MicroRNAs (miRNAs) are small (~22 nt) noncoding single-stranded RNA molecules that downregulate gene expression. Studies have shown that miRNAs control diverse aspects of heart disease, including hypertrophy, remodeling, heart failure, and arrhythmia. Recently, several studies have suggested that miRNAs contribute to ischemia-reperfusion injury by altering key signaling elements, thus making them potential therapeutic targets. By altering the expression of various key elements in cell survival and apoptosis [such as phosphoinositide 3-kinase (PI3K), phosphatase and tensin homolog deleted on chromosome 10 (PTEN), Bcl-2, Mcl-1, heat shock protein (HSP)60, HSP70, HSP20, programmed cell death 4 (Pdcd4), LRRFIP1, Fas ligand (FasL), Sirt-1, etc.], miRNAs alter the response to ischemia-reperfusion injury. Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a, miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction. Thus miRNAs could be potential therapeutic targets for the treatment of heart disease. Inhibiting miRNAs by antisense strategies or pharmacological approaches is likely to emerge as an alternative and safe method for conferring short- and intermediate-term protection against ischemia-reperfusion injury.",
keywords = "Infarct size, Myocardial infarction",
author = "Yumei Ye and Perez-Polo, {Jose R.} and Jinqiao Qian and Yochai Birnbaum",
year = "2011",
month = "5",
doi = "10.1152/physiolgenomics.00130.2010",
language = "English (US)",
volume = "43",
pages = "534--542",
journal = "Physiological Genomics",
issn = "1094-8341",
publisher = "American Physiological Society",
number = "10",

}

TY - JOUR

T1 - The role of microRNA in modulating myocardial ischemia-reperfusion injury

AU - Ye, Yumei

AU - Perez-Polo, Jose R.

AU - Qian, Jinqiao

AU - Birnbaum, Yochai

PY - 2011/5

Y1 - 2011/5

N2 - MicroRNAs (miRNAs) are small (~22 nt) noncoding single-stranded RNA molecules that downregulate gene expression. Studies have shown that miRNAs control diverse aspects of heart disease, including hypertrophy, remodeling, heart failure, and arrhythmia. Recently, several studies have suggested that miRNAs contribute to ischemia-reperfusion injury by altering key signaling elements, thus making them potential therapeutic targets. By altering the expression of various key elements in cell survival and apoptosis [such as phosphoinositide 3-kinase (PI3K), phosphatase and tensin homolog deleted on chromosome 10 (PTEN), Bcl-2, Mcl-1, heat shock protein (HSP)60, HSP70, HSP20, programmed cell death 4 (Pdcd4), LRRFIP1, Fas ligand (FasL), Sirt-1, etc.], miRNAs alter the response to ischemia-reperfusion injury. Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a, miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction. Thus miRNAs could be potential therapeutic targets for the treatment of heart disease. Inhibiting miRNAs by antisense strategies or pharmacological approaches is likely to emerge as an alternative and safe method for conferring short- and intermediate-term protection against ischemia-reperfusion injury.

AB - MicroRNAs (miRNAs) are small (~22 nt) noncoding single-stranded RNA molecules that downregulate gene expression. Studies have shown that miRNAs control diverse aspects of heart disease, including hypertrophy, remodeling, heart failure, and arrhythmia. Recently, several studies have suggested that miRNAs contribute to ischemia-reperfusion injury by altering key signaling elements, thus making them potential therapeutic targets. By altering the expression of various key elements in cell survival and apoptosis [such as phosphoinositide 3-kinase (PI3K), phosphatase and tensin homolog deleted on chromosome 10 (PTEN), Bcl-2, Mcl-1, heat shock protein (HSP)60, HSP70, HSP20, programmed cell death 4 (Pdcd4), LRRFIP1, Fas ligand (FasL), Sirt-1, etc.], miRNAs alter the response to ischemia-reperfusion injury. Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a, miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction. Thus miRNAs could be potential therapeutic targets for the treatment of heart disease. Inhibiting miRNAs by antisense strategies or pharmacological approaches is likely to emerge as an alternative and safe method for conferring short- and intermediate-term protection against ischemia-reperfusion injury.

KW - Infarct size

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=79957631904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957631904&partnerID=8YFLogxK

U2 - 10.1152/physiolgenomics.00130.2010

DO - 10.1152/physiolgenomics.00130.2010

M3 - Article

VL - 43

SP - 534

EP - 542

JO - Physiological Genomics

JF - Physiological Genomics

SN - 1094-8341

IS - 10

ER -